Table 1 Clinical characteristics of AML patients respect to RCC1 expression
Characteristics | total (n = 77) | low RCC1 expression (n = 57) | high RCC1 expression (n = 20) | p-value |
|---|---|---|---|---|
| Â | n (%) or median (range) | n (%) or median (range) | n (%) or median (range) | Â |
Gender (Male) | 40 (51.9%) | 29 (550.9%) | 11 (55.0%) | 0.799 |
Age (years) | 60 (18–86) | 60 (18–81) | 67.5 (24–86) | 0.093 |
WBC (× 109/L) | 7.71 (0.4–123.6) | 7.79 (0.4–123.6) | 6.0 (0.69–100.4) | 0.830 |
Hb (g/L) | 75 (36–152) | 75 (36–124) | 77 (42–152) | 0.693 |
Plt (× 109/L) | 53 (3–259) | 50 (3–259) | 53.3 (15–140) | 0.542 |
BM blast (%) | 46 (6.05–96) | 43 (6.05–94.8) | 72.4 (12.4–96) | 0.027 |
FAB | Â | Â | Â | Â |
M1 | 7 (9.09%) | 3 (5.26%) | 4 (20.0%) | 0.086 |
M2 | 40 (51.9%) | 30 (52.6%) | 10 (50.0%) | Â |
M4 | 5 (6.49%) | 5 (8.77%) | 0 (0.00%) | Â |
M5 | 24 (31.2%) | 19 (33.3%) | 5 (25.0%) | Â |
M7 | 1 (1.30%) | 0 (0.00%) | 1 (5.00%) | Â |
2017 ELN risk stratification | Â | Â | Â | Â |
favorable | 19 (24.7%) | 18 (31.6%) | 1 (5.00%) | 0.008 |
intermediate | 25 (32.5%) | 20 (35.1%) | 5 (25.0%) | Â |
adverse | 33 (42.9%) | 19 (33.3%) | 14 (70.0%) | Â |
Treatment response | Â | Â | Â | Â |
CR | 59 (76.6%) | 48 (84.2%) | 11 (55.0%) | 0.001 |
PR | 5 (6.49%) | 0 (0.00%) | 5 (25.0%) | Â |
NR | 13 (16.9%) | 9 (15.8%) | 4 (20.0%) | Â |